Navigation Links
Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients
Date:4/18/2013

LAUSANNE, Switzerland and SUZHOU, China, April 18, 2013 /PRNewswire/ --

Suzhou Ascepion Pharmaceuticals, Inc. (Ascepion), a Chinese leading biotech company focusing on the discovery and development of world-class molecular targeted innovative drugs and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies, announced today that Debiopharm will support further development in China of Debio 1144, a small molecule in preclinical development for the treatment of a large spectrum of solid tumors.

Debiopharm and Ascepion had previously signed a license agreement for the development and commercialization of Debio 1144, an orally available multikinase inhibitor. After having generated positive preclinical results with the product, Debiopharm has decided to support Ascepion for further development of Debio 1144 in China as it is well designed for the treatment of certain types of cancers that are highly represented in China. 

"This is an opportunity for Ascepion to develop an anti-cancer agent tailored to the Chinese market," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "At Debiopharm we value sharing our competences with a Chinese company in view of developing a product with a potential to treat various cancers highly prevalent in emerging markets."

"The disease spectrum of the Chinese population suggests the product will be well suited for its market. Thus it holds a great promise for certain cancer types in Chinese patients," commented Dr. Shan Jiang , President and CEO of Ascepion Pharmaceuticals.

About Debio 1144

Debio 1144 is a multikinase inhibitor, which has demonstrated strong efficacy in several preclinical models. It is orally available and has a large therapeutic index.

About Suzhou Ascepion Pharmaceuticals Inc.

Based in Suzhou, China, Suzhou Ascepion Pharmaceuticals, Inc. is a leading biopharmaceutical company in China dedicated to the discovery and development of breakthrough small molecule drugs. Suzhou Ascepion Pharmaceuticals possesses a fully integrated platform and proprietary technologies for the discovery and development of small molecule therapeutics targeting signal transduction pathways in a systematic and productive manner. The company has developed a pipeline of innovative small molecule drugs for the treatment of oncology and related diseases. For additional information on Suzhou Ascepion Pharmaceuticals, please visit http://www.ascepion.com.

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact    
Mrs Beatrice Hirt
Communication Coordinator
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
bhirt@debiopharm.com
Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf , Ph.D.
Account Executive
Tel: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com


Ascepion Contact
Ms. Min Wang
Corporate administration
Tel.: +86-512-62956001
Fax: +86-512-62956001-8004
mwang@ascepion.com



'/>"/>
SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
2. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
3. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
4. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Watson to Acquire Actavis Group for EUR4.25 Billion
7. CentraState and Freehold Radiology Group train physicians from China
8. Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT
9. Okuma America Chooses The Daniel Group To Provide Customer Service Research
10. H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
11. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Abdominal Aortic Aneurysm Repair Devices ... by 2022, Globally, registering a CAGR of 5.1% from 2016 to 2022. The endovascular ... to dominate the market during the study period. Continue ... ... ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to gain popularity. A ... market will reach a value of USD 55.8 billion by 2025. ... growing industry. By the end of 2016, 28 states have now laws ... conservative states like Arkansas and North ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner ... in Frederick, MD. Judy says, “I am passionate about sharing Reiki as a ... very difficult and challenging time.” , A Certified Medical Reiki™ Master trained by ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of published author, ... his wife, Anna Marie. He and his wife are the proud parents of four ... of “Shadow and Substance.” , “Love, the agape kind, is seen as more than ...
(Date:3/23/2017)... & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... health emergency and now estimates that there could be four million Zika-related cases in ... epidemics to date with numbers of US cases reported per year skyrocketing to an ...
(Date:3/23/2017)... Alexandria, Virginia (PRWEB) , ... March 23, 2017 ... ... quality public health services to their communities, 16 more public health departments have ... This week’s decisions bring another 4.5 million people into the expanding network of ...
(Date:3/23/2017)... ... 2017 , ... The IoT (Internet of Things) is revolutionizing the way the ... on businesses and individual consumers alike. Laboratories can maximize their profit margin by ... from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the ...
Breaking Medicine News(10 mins):